Publisher
Springer Science and Business Media LLC
Reference83 articles.
1. Agrawal, M. et al. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Journal of controlled release 281, 139–177 (2018).
2. Di Domenico, F., Barone, E., Perluigi, M. & Butterfield, D. A. The triangle of death in Alzheimer’s disease brain: the aberrant cross-talk among energy metabolism, mammalian target of rapamycin signaling, and protein homeostasis revealed by redox proteomics. Antioxidants & redox signaling 26, 364–387 (2017).
3. San Chang, Y., Wu, Y. H., Wang, C. J., Tang, S. H. & Chen, H. L. Higher levels of thyroxine may predict a favorable response to donepezil treatment in patients with Alzheimer disease: a prospective, case–control study. BMC neuroscience 19, 36 (2018).
4. Espinoza, L. C. et al. Development of a Nasal Donepezil-loaded Microemulsion for the Treatment of Alzheimer’s Disease: in vitro and ex vivo Characterization. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 17, 43–53 (2018).
5. Ruela, A. L. M., de Figueiredo, E. C., de Araújo, M. B., Carvalho, F. C. & Pereira, G. R. Molecularly imprinted microparticles in lipid-based formulations for sustained release of donepezil. European Journal of Pharmaceutical Sciences 93, 114–122 (2016).
Cited by
82 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献